Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS opened at $0.54 on Wednesday. The company has a market capitalization of $5.81 million, a PE ratio of -0.07 and a beta of 1.62. Ayala Pharmaceuticals has a one year low of $0.50 and a one year high of $1.95. The company’s fifty day moving average price is $0.70 and its 200 day moving average price is $0.74.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.